Cholesterol reduction and clinical benefit. Are there limits to our expectations?

Arteriosclerosis, Thrombosis, and Vascular Biology
G Fager, O Wiklund

Abstract

Encouraging intervention trials drive our expectations toward more aggressive cholesterol-lowering therapies, lower target levels, and less severe hypercholesterolemia. Available studies may predict which patients, degrees of total cholesterol (TC) reduction, and baseline and target levels of TC provide the most clinical benefit. Data were pooled from seven primary and nine secondary controlled trials with major coronary heart disease (CHD) events as primary endpoints. The analysis showed that we can expect large reductions in CHD from TC reduction in primary and secondary prevention. However, the reduction is much larger in subjects with high TC and/or previous CHD events. The percent reduction in CHD increased exponentially with increasing percent TC reductions, which predicted > 70% of the change in CHD. Consequently, we cannot expect cost-effective clinical benefits from mean reductions in TC > 15 (LDL cholesterol > 20%). The TC level at the study endpoint correlated with CHD incidence irrespective of the study group and explained almost 45% of CHD incidence. The relationship was progressive and leveled off at a TC level below about 150 mgdL (3.9 mmol/L) (LDL cholesterol approximately equal to 110 mg/dl [approximately equal...Continue Reading

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Apr 1, 1986·European Heart Journal·L WilhelmsenL Werkö
Sep 28, 1995·The American Journal of Cardiology·I Holme
Sep 28, 1995·The American Journal of Cardiology·J Kjekshus, T R Pedersen

❮ Previous
Next ❯

Citations

Sep 15, 2005·Heart and Vessels·San-Chiang WuChun-Peng Liu
Oct 12, 2000·Journal of the American College of Cardiology·J S ForresterS Kaul
Apr 18, 2001·American Journal of Preventive Medicine·UNKNOWN US Preventive Services Task Force
Jun 19, 2003·Journal of Clinical Epidemiology·Valerie BurkeStephen Houghton
Apr 7, 1999·Current Opinion in Cardiology·P W Wilson
Jul 31, 2013·Journal of Atherosclerosis and Thrombosis·Tamio TeramotoKoutaro Yokote
Mar 27, 1999·Scandinavian Cardiovascular Journal : SCJ·L Erhardt, P Nilsson
Oct 27, 2015·BMC Family Practice·Julia Bóveda-FontánUNKNOWN Collaborative Group Estudio Dislip-EM
Oct 16, 2016·Metabolic Syndrome and Related Disorders·Toyoko MoritaMasao Maeno
Jun 26, 2007·Atherosclerosis. Supplements·Y MatsuzawaJ Sasaki
Jan 20, 2009·Heart & Lung : the Journal of Critical Care·Xingang ZhangYingxian Sun
Aug 24, 2018·Journal of Atherosclerosis and Thrombosis·Makoto KinoshitaUNKNOWN Committee for Epidemiology and Clinical Management of Atherosclerosis
Jan 14, 2021·Chronobiology International·Elissa K HoopesFreda Patterson
Apr 18, 2001·American Journal of Preventive Medicine·M P PignoneK N Lohr
May 20, 2021·Journal of Human Hypertension·Yoji YamazakiTakayuki Kawato

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.